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Abstract This study aimed to explore the protective
effect of hydrogen as an antioxidant on monocrotaline
(MCT)-induced pulmonary hypertension (PH). Forty-eight
SD rats were equally randomized into four groups: SHAM
group, MCT group, MCT?Oral-H2 group and MCT?Inj-
H2 group. The results showed that the mean pulmonary
arterial pressure, right ventricle weight and right ventric-
ular hypertrophy index in MCT group were significant
higher than those in SHAM group; pulmonary inflamma-
tory response, atrial natriuretic factor, 3-nitrityrosine and
intercellular adhesion molecule-1 were also increased sig-
nificantly in MCT group. These indexes were decreased
significantly in both MCT?Oral-H2 group and MCT?Inj-
H2 group, which indicate Oral-H2 and Inj-H2 have similar
effects of preventing the development of PH and mitigating
RV hypertrophy. The protective effect of hydrogen is
associated with its antioxidative ability and action of
reducing pulmonary inflammatory response. While Oral-H2
is more convenient than Inj-H2, Oral-H2 may be ideal for
clinical use in future.
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Introduction
Pulmonary hypertension (PH) is clinically characterized by
progressive increase of pulmonary arterial pressure and
right ventricular hypertrophy [1]. It is believed that PH is a
severe condition attributable to co-action of multiple eti-
ologies and factors, including genetic susceptibility,
immunologic disturbances and environmental stimuli [2–
6]. Previous studies mainly focused on the use of vasodi-
lators [7–9], including nitric oxide inhalation, and use of
cyclic guanosine monophosphate generating agents, endo-
thelin receptor antagonists and prostatin. However, these
vasodilators were unable to radically reverse the progres-
sive increase of PH. It is therefore necessary to find a new
strategy that could cure PH effectively and prevent pul-
monary vascular resistance from rising progressively [10].
Studies [11–14] have demonstrated that reactive oxygen
species (ROS) plays an important role in the occurrence of
PH, and those antioxidants are effective in the treatment of
PH [15, 16]. However, the use of large doses of non-selective
antioxidants may induce hemorrhage and other complica-
tions [17, 18], and therefore rational use of selective anti-
oxidants is more advantageous in the treatment of PH.
Recent studies [19–21] have shown that molecular hydrogen
is a selective antioxidant, and plays a role in protecting
against ischemia/reperfusion (I/R) injury through selectively
clearing hydroxyl radicals (OH) and peroxynitrite (ONOO-
); and hydrogen does not react with other ROS (e.g., H2O2
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and O2-), which possess physiological roles. Our previous
study [22] also demonstrated that intraperitoneal Inj-H2
could protect against I/R injury through selective anti-oxi-
dization. So we established a PH rat model by intraperitoneal
injection of monocrotaline (MCT) to see whether hydrogen
was also effective in PH treatment.
There are various ways [19–22] to administrate molec-
ular hydrogen as a therapeutic antioxidant, inhalation of
hydrogen gas, oral administration of hydrogen water,
intraperitoneal or intravenous injection of hydrogen-rich
saline. As hydrogen gas is explosive, this might be
potential dangerous for clinical application. Besides using
Inj-H2 in our previous study [22], we also made new
modification in production and administration of hydrogen
by using Oral-H2 in the present study. And we will also
compare these two different ways to administrate hydrogen
in therapeutic effect on MCT-induced PH.
Materials and methods
Animals
Adult SD rats weighing 250–280 g (Experimental Animal
Center of the Second Military Medical University,
Shanghai, China) were housed with free access to food and
water under a natural day/night cycle, and acclimated for
7 days before any experimental procedure. All experi-
mental procedures were approved by the Institutional
Animal Care and Use Committee of the Second Military
Medical University in Shanghai, China.
Production of Oral-H2 and Inj-H2
Oral-H2 [20]: The magnesium stick used to produce hydro-
gen in the study was a plastic-shelled product consisting of
metallic magnesium (99.9 % pure) and natural stones in a
polypropylene container combined with ceramics (Doctor
SUISOSUI, Friendear, Tokyo, Japan). It was able to gen-
erate hydrogen when placed in drinking water through the
following chemical reaction: Mg ? 2H2O ? M-
g(OH)2 ? H2. The hydrogen concentration in the water
bottle was sequentially monitored using a hydrogen needle
sensor (DHS-001, ABLE, Tokyo, Japan) and maintained at a
level between 0.55 and 0.65 mmol and pH 7.7–8.3.
Inj-H2 [22]: Hydrogen was dissolved in 0.9 % saline for
6 h under a high pressure (0.4 MPa) to a supersaturated
level. Hydrogen saline was stored under an atmospheric
pressure at 4 C in an aluminum bag with no dead volume,
sterilized by gamma radiation, and freshly prepared once a
week to ensure that the concentration was maintained at
0.6 mmol/L. Gas chromatography was performed to con-
firm the content of hydrogen in saline.
Establishment of the in vivo rat model
and experimental protocols
Forty-eight SD rats were equally randomized to four
groups: SHAM group as the control, MCT group,
MCT?Oral-H2 group and MCT?Inj-H2 group. Animals in
SHAM group were administered with Oral-H2 only, and
the other groups were administered with intraperitoneal
injection of MCT (80 mg/kg).
Fourteen days later, the mean pulmonary arterial pres-
sure (mPAP) was measured in all the groups. Animals in
MCT group were administered with ordinary drinking
water thereafter. Those in MCT?Oral-H2 group or
MCT?Inj-H2 group were administered with Oral-H2 or
Inj-H2 respectively.
Additional 14 days later, mPAP was measured again.
All animals were then sacrificed, and the heart and lung
tissue were removed for morphologic observation and
related tests.
Determination of mPAP
The rats were anesthetized by intraperitoneal injection of
300 mg/kg chloral hydrate and fixed in a supine position.
The right jugular vein was isolated, through which a PE50
catheter was inserted to the right ventricle (RV) to the right
atrium, and finally placed in the pulmonary trunk. The end
of the catheter was connected to a pressure sensor to
monitor, analyze and record mPAP in a real-time manner.
Measurement of RVHI
The RV, left ventricle (LV) and septum (S) were weighed
separately. The right ventricular hypertrophy index (RVHI)
was measured by RV/(LV?S) weight.
Histopathology of lung injury and RV hypertrophy
Lung injury [23] The pulmonary tissues were stained with
HE. Morphological lung injury in different groups was
assessed by at least two pathologists independently
according to the procedures described previously.
Determination of ANF Besides RVHI, ANF is another
marker for RV hypertrophy. Blood for plasma atrial
natriuretic factor (ANF) measurements were collected in
heparinized syringes. Plasma was separated by centrifu-
gation and frozen at -70 C. Plasma ANF was measured
by ELISA method (Abcam Inc.) [24].
Determination of 3-nt and ICAM-1 levels
Immunohistochemistry The rats were sacrificed, and the
lung tissue was sliced, fixed, paraffin-embedded and
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dewaxed routinely as described [22]. The primary anti-
bodies for the determination of 3-nitrityrosine (3-nt) and
intercellular adhesion molecule-1 (ICAM-1) were products
of Abcam Inc., and the secondary antibodies were products
of R&D Systems. The prepared immunohistochemical
sections were observed in randomly selected four fields
(920), and the number of 3-nt and ICAM-1 positive cells
was counted quantitatively.
Western blot The protein expression of 3-nt and ICAM-
1 was detected similar to our previous study [25]. All the
same membranes were probed with b-actin as loading
controls.
Statistical analysis
Quantitative data were expressed as mean ± SD. Differ-
ences within the three groups were determined with one-
way ANOVA and Student–Newman–Keuls test. P \ 0.05
was considered statistically significant.
Results
MPAP and RVHI measurement
Fourteen days after intraperitoneal injection of MCT,
mPAP in MCT, MCT?Oral-H2 and MCT?Inj-H2 groups
was 29.6 ± 7.2 mmHg, 28.4 ± 8.5 mmHg and
29.1 ± 8.7 mmHg respectively. They were all significantly
higher than that in SHAM group which was
18.6 ± 4.3 mmHg (P \ 0.05), indicating successful
establishment of PH animal model. There was no signifi-
cant difference in mPAP within MCT group, MCT?Oral-
H2 group and MCT?Inj-H2 group (P [ 0.05).
After additional 14 days, mPAP and RVHI were mea-
sured again. As shown in Table 1, mPAP, RV and RVHI in
MCT group were all significantly higher than those in
SHAM group (P \ 0.05). While these indexes were
decreased significantly in MCT?Oral-H2 group and
MCT?Inj-H2 group (P \ 0.05), indicating that both Oral-
H2 and Inj-H2 can alleviate MCT-induced PH. There was
no significant difference between MCT?Oral-H2 group
and MCT?Inj-H2 group (P [ 0.05), which indicate Oral-
H2 and Inj-H2 have similar protective effect on PH.
Assessment of RV hypertrophy
PH can induce RV hypertrophy. Besides RVHI, ANF is
another marker for RV hypertrophy. Plasma ANF was
detected by ELISA method. The results showed that ANF
in MCT group was significantly higher than that in SHAM
group (P \ 0.05). While ANF was decreased significantly
in MCT?Oral-H2 group and MCT?Inj-H2 group than in
MCT group (P \ 0.05) (Table 1).
Determination of 3-nt
Immunohistochemistry for 3-nt was performed on biopsies
obtained from the lungs. The number of 3-nt positive cells
in MCT group were significantly greater than that in
SHAM group, with a positive rate of 66 ± 11 %
(P \ 0.05), indicating that nitrative stress in MCT group
was increased. While the number of 3-nt positive cells in
MCT?Oral-H2 group and MCT?Inj-H2 group were sig-
nificantly lower than that in MCT group, with a positive
rate of 42 ± 8 % and 44 ± 7 % respectively (P \ 0.05),
indicating that both Oral-H2 and Inj-H2 can mitigate the
nitrative stress in the course of PH formation (Fig. 1a, b).
The protein expression of 3-nt in different groups was
determined by western blot. The protein expression of 3-nt
in MCT group was up-regulated than that in SHAM group,
while both Oral-H2 and Inj-H2 can down-regulate the
expression of 3-nt (Fig. 1c).
Determination of ICAM-1
Immunohistochemistry for ICAM-1 was performed. The
number of ICAM-1 positive cells in MCT group were
significantly greater than that in SHAM group, with a
positive rate of 28 ± 5 % (P \ 0.05), implying that
Table 1 General results obtained at day 28
SHAM group MCT group MCT?Oral-H2 group MCT?Inj-H2 group
Body weight (g) 321 ± 8.6 275 ± 11.6* 281 ± 13.8* 288 ± 13.4*
Heart weight (g) 0.93 ± 0.042 1.17 ± 0.073* 1.11 ± 0.061* 1.13 ± 0.065*
RV weight (g) 0.18 ± 0.004 0.438 ± 0.051* 0.346 ± 0.041*ł 0.349 ± 0.040*ł
LV ? S weight (g) 0.751 ± 0.031 0.734 ± 0.021 0.755 ± 0.032 0.745 ± 0.028
RVHI 0.24 ± 0.014 0.59 ± 0.065* 0.45 ± 0.048*ł 0.47 ± 0.052*ł
mPAP (mmHg) 19.8 ± 5.1 44.6 ± 7.2* 31.4 ± 6.5*ł 32.2 ± 6.7*ł
Plasma ANF (pg/ml) 185.6 ± 53.8 693.7 ± 165.9* 407.2 ± 102.3*ł 423.4 ± 114.0*ł
* P \ 0.05 compared with SHAM group; ł P \ 0.05 compared with MCT group
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ICAM-1 infiltration was increased in MCT group. The
number of ICAM-1 positive cells in MCT?Oral-H2 group
and MCT?Inj-H2 group were significantly lower than that
in MCT group, with a positive rate of 13 ± 3 % and
12 ± 3 % respectively (P \ 0.05), suggesting that both
Oral-H2 and Inj-H2 can mitigate ICAM-1 infiltration in the
course of PH formation (Fig. 2a, b).
The protein expression of ICAM-1 in different groups
was determined by Western blot. The protein expression of
ICAM-1 in MCT group was up-regulated than that in
Fig. 1 3-nt levels in different
groups.
a Immunohistochemistry. The
inset in the lower right corner of
the figure showed a section at
larger scales, and arrows to
show the positive cells.
b Positive rate. The number of
3-nt positive cells in MCT
group was significantly greater
than that in SHAM group, and
the number of 3-nt positive cells
in MCT?Oral-H2 and
MCT?Inj-H2 groups was
significantly lower than that in
MCT group. c Western blot.
The protein expression of 3-nt
in MCT group was up-regulated
than that in SHAM group, while
both Oral-H2 and Inj-H2 can
down-regulate the expression of
3-nt. (*P \ 0.05 compared with
SHAM group; łP \ 0.05
compared with MCT group)
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SHAM group, while both Oral-H2 and Inj-H2 can down-
regulate the expression of ICAM-1 (Fig. 2c).
Analysis and scoring of lung tissue injury
There was no significantly abnormal change in lung tissue
was observed in SHAM group, while there was significant
evidence of inflammatory response in the lung tissue of the
rats in MCT group, presenting as fracture of parenchymal
cells, infiltration of macrophages and chronic inflammatory
cells, and significant thickening of alveolar septa and
cavities. Compared with MCT group, these inflammatory
responses were significantly ameliorated in both
MCT?Oral-H2 group and MCT?Inj-H2 group (Fig. 3a).
The tissue injury score was 11 ± 5 in SHAM group,
25 ± 7 in MCT group, 18 ± 6 in MCT?Oral-H2 group
Fig. 2 ICAM-1 levels in
different groups.
a Immunohistochemistry. The
inset in the lower right corner of
the figure showed a section at
larger scales, and arrows to
show the positive cells.
b Positive rate. The number of
ICAM-1 positive cells in MCT
group was significantly greater
than that in SHAM group, and
the number of ICAM-1 positive
cells in MCT?Oral-H2 and
MCT?Inj-H2 groups was
significantly smaller than that in
MCT group. c Western blot.
The protein expression of
ICAM-1 in MCT group was up-
regulated than that in SHAM
group, while both Oral-H2 and
Inj-H2 can down-regulate the
expression of ICAM-1.
(*P \ 0.05 compared with
SHAM group; łP \ 0.05
compared with MCT group)
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and 17 ± 5 in MCT?Inj-H2 group, which indicated that
tissue injury in MCT group was more severe than that in
SHAM group (P \ 0.05), while that in MCT?Oral-H2
group and MCT?Inj-H2 group was ameliorated signifi-
cantly (P \ 0.05) (Fig. 3b).
Discussion
Inflammatory response in lung tissue, progressive increase
of pulmonary arterial pressure and pulmonary vascular
resistance, resultant RV hypertrophy and remodeling are
typical pathological presentations of PH [26]. RVHI and
plasma ANF were detected, both of which are markers for
RV hypertrophy. Both RVHI and ANF were decreased
significantly by hydrogen. These results of the present
study showed that hydrogen can relieve MCT-induced PH
markedly and reverse RV hypertrophy. It was found in our
experiment that hydrogen was able to reduce the thickness
of alveolar septa and the number of chronic inflammatory
cells in the course of PH formation, thus mitigating RV
hypertrophy. Knowing that ROS is closely correlated with
RV hypertrophy as demonstrated in previous studies [27],
and that hydrogen can clear ROS, we suppose that the
mechanism of hydrogen in mitigating RV hypertrophy is
via selectively clearing ROS and reducing pulmonary
arterial pressure. As a result, not only RV load was reduced
but RV hypertrophy was mitigated.
Fig. 3 Results of lung tissue
injury. a HE Staining. In SHAM
group, the lung tissue was
normal. In MCT group,
inflammatory injury to the lung
tissue was severe, presenting as
fracture of the alveolar septa
and infiltration of macrophages
and chronic inflammatory cells
as indicated by the presence of





arterioles. In the lung tissue
sections of MCT?Oral-H2 and
MCT?Inj-H2 groups, the
number of inflammatory cells
was reduced significantly, and
alveolar septa were also reduced
significantly as compared with
SHAM group. b Lung injury
score. Semi-quantitative scoring
of the lung tissue in different
groups showed that the lung
tissue injury score of MCT
group was significantly higher
than that of SHAM group, and
the lung tissue injury score of
MCT?Oral-H2 and MCT?Inj-
H2 groups was significantly
lower than that of MCT group
(*P \ 0.05 compared with
SHAM group; łP \ 0.05
compared with MCT group)
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Previous studies have demonstrated that chronic
inflammatory response plays an crucial role in the devel-
opment and progression of PH [2], and that increased ROS
production is inextricably associated with chronic inflam-
matory response [28], which is also confirmed by the fact
that antioxidants are effective in the treatment of PH [15,
23]. Our previous experiment [22] demonstrated that
molecular hydrogen had an anti-inflammatory effect on I/R
injury. The present study further confirmed that molecular
hydrogen was able to mitigate the infiltration of inflam-
matory cells in the course of MCT-induced PH formation,
thus relieving inflammatory response. ICAM-1 is one of
the main adhesion molecules mediating neutrophil adhe-
sion, and is regulated by such cytokines as TNF-a and IL-
1b. After cytokine regulation, ICAM-1 is up-regulated
rapidly, thus progressively aggravating the inflammatory
response. If ICAM-1 could be reduced effectively,
inflammatory response in the course of pathological injury
would be mitigated [29, 30]. It was found in the present
study that hydrogen could reduce ICAM-1 level in the
course of PH formation and infiltration of chronic inflam-
matory cells in local lung tissue, thus relieving the severity
of PH.
It was also found in our study that improvement of PH
was significantly correlated with 3-nt level. 3-nt is a spe-
cific metabolic product of ONOO-, reflecting the level of
nitrative stress in vivo [31]. The fact that hydrogen could
effectively relieve MCT-induced PH implies that ONOO-
plays an important role in the development and progression
of PH. There are various types of ROS produced in vivo,
including hydroxyl free radical, ONOO-, peroxide and
superoxide anion. But which ROS actually plays a role in
the development and progression of PH remains unclear.
Previous related studies mainly focused on the use of
antioxidants, and few studies have focused on which ROS
or how many ROS playing the role. The present study
demonstrated that hydrogen could reduce 3-nt level
markedly and mitigate the pathological process of PH,
which indirectly proves that ONOO- may participate in PH
formation. It is noteworthy that some studies [32] also
found that ONOO- played an important role in chronic
inflammation, which may explain why reducing ONOO-
level could mitigate the severity of PH.
Although studies showed that some antioxidants could
effectively reduce PH, few of them have been used clini-
cally. Imbalance in the endogenous redox state due to
nonselective clearance is supposed to be the main reason
for failure of some antioxidants in the treatment of PH [33,
34]. Selective clearance is therefore the rational method for
effective treatment of PH. It has been proved [19] that
molecular hydrogen is a selective antioxidant, which can
selectively clear OH and ONOO-. And hydrogen does not
react with other ROS, which possess physiological roles. In
addition, due to the small molecular weight, hydrogen can
easily enter cell membrane and organelle membrane. These
are the advantages of hydrogen in playing antioxidative
effect on PH.
In our previous study [22], we used intraperitoneal Inj-
H2 as an antioxidant. In the present study, we made new
modification in production and administration of hydrogen
by using oral hydrogen water (Oral-H2) generated by
magnesium stick. The results showed Oral-H2 and Inj-H2
have similar effect of preventing the development of PH
and mitigating RV hypertrophy.
As shown in Table 2, we also compared between the
two different ways to administrate hydrogen (Oral-H2 and
Inj-H2). Unlike Inj-H2, The administration and absorption
of Oral-H2 are non-invasive and physiological. As hydro-
gen can also be produced in the human intestinal tract, it is
safe to drink a certain amount of Oral-H2. Inj-H2 needs
high pressure (0.4 MPa) to produce, and is stored under
atmospheric pressure at 4 C in an aluminum bag without
dead volume. While the production and storage of Oral-H2
are more convenient, just under normal pressure and nor-
mal temperature. The release time of Inj-H2 is transient,
need freshly preparation every week to ensure a constant
Table 2 Comparison between two different ways to administrate hydrogen
Oral-H2 Inj-H2
Administration & absorption Oral administration is non-invasive; gastrointestinal
tract absorption is physiological
Injection is invasive; intraperitoneal or intravenous
absorption is non-physiological
Production & storage Convenient; normal pressure; normal temperature Need more higher pressure to produce; storage at
4 C; need special instrument to store: aluminum
bag without dead volume
Release time Continuous; release hydrogen as long as magnesium
stick not depleted
Transient; need freshly preparation every week to
ensure a constant concentration of greater than
0.6 mM
Cost Less; only 10–15 % price of Inj-H2 More
Clinical application Ideal and convenient for patients without changing
their lifestyle
Need injection everyday
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concentration of greater than 0.6 mM. While Oral-H2 can
release hydrogen continuously as long as magnesium stick
not depleted. And the cost of Oral-H2 is only 10–15 %
price of Inj-H2. Oral-H2 is more convenient, less costly and
longer release time than Inj-H2, and drinking water con-
taining a high concentration of hydrogen is a novel, safe
and potent approach for the prevention and treatment of
PH, so Oral-H2 may be more ideal for patients in future, as
it can be administered without changing their lifestyle.
In summary, the results of the present experiment
showed that hydrogen can reduce PH, mitigate RV
hypertrophy by reduce RVHI and ANF in a MCT-induced
PH rat model. In addition, hydrogen could reduce inflam-
matory response and 3-nt and ICAM-1 levels in the course
of PH formation, suggesting that the therapeutic effect of
hydrogen in the treatment of PH is closely correlated with
antioxidative stress. While Oral-H2 is more convenient
than Inj-H2, so Oral-H2 may be more ideal for clinical use
in future. Next step, we plan to make in-depth study on the
mechanism of hydrogen in reducing PH, especially the
influence of hydrogen on cytokines that are closely asso-
ciated with PH.
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